Pegram Unpacks Pivotal Data in Breast Cancer
Season 3, Episode 30, Aug 17, 2020, 06:14 PM
In our exclusive interview, Dr. Pegram discusses the unique structure of trastuzumab deruxtecan, initial and subset analyses from the DESTINY-Breast01 trial, and potential adverse effects and recommended management strategies for the agent.